Trial Profile
Significance of the Aspartate Aminotransaminase (AST)/Alanine Aminotransaminase (ALT) ratio (De Ritis ratio) as a biomarker for mCRPC patients receiving Cabazitaxel
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jul 2018
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 23 Jul 2018 New trial record
- 01 Jul 2018 Results published in the Anticancer Research